Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
November 25 2022 - 8:08AM
Business Wire
New Affirm® Contrast Biopsy Technology Included
in the Screening, Diagnosis, Treatment and Monitoring Solutions on
Display
Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive
portfolio of breast and skeletal health products at the 108th
Scientific Assembly and Annual Meeting of the Radiological Society
of North America (RSNA) from Nov. 27 to Dec. 1. Among the full
suite of breast biopsy and surgery solutions will be Hologic’s
Affirm® Contrast Biopsy software, which will be on
display for the first time since becoming commercially available in
the United States.
“As the global leader in breast imaging, we are committed to
addressing the unmet needs of physicians and their patients across
the continuum of breast care and we’re eager to engage with
industry leaders at this year’s RSNA meeting to share our vision
for the future of breast health,” said Erik Anderson, President of
Hologic’s Breast and Skeletal Health Solutions Division. “We are
equally excited to showcase our new Affirm Contrast Biopsy
technology, which is a great example of our commitment to
physicians and patients in action.”
Affirm Contrast Biopsy software allows clinicians to target and
acquire tissue samples in lesions identified with
I-View® Contrast-Enhanced Mammography software. The
contrast solution provides healthcare facilities with a viable and
attractive alternative to breast MRI, which historically has been
used to find and biopsy more elusive lesions, such as those that
cannot be seen via mammography or ultrasound. While breast MRI can
be time-consuming and costly, contrast technology gives
radiologists another option in the mammography suite that addresses
these shortcomings.1,2 In a recent clinical study, 98% of patients
had an overall positive opinion of their procedure experience with
Affirm Contrast Biopsy software.3
RSNA attendees can experience Hologic’s portfolio at Booth 1911
in South Hall Level 3 at McCormick Place in Chicago. In addition to
the Affirm Contrast Biopsy software, Hologic will feature its
Dimensions® mammography portfolio and Supersonic®
MACH™ ultrasound systems.
Hologic will also host a series of CME- and non-CME-accredited
medical education symposiums and learning opportunities, accessible
to attendees on-site and from remote locations. The medical
education sessions include:
- “Upright Biopsy with Brevera® Breast Biopsy System:
Real-Time Imaging, Verification & Automated Handling”
Sunday, Nov. 27: 11:45 a.m. – 12:45 p.m. CST Dr. Krystal Airola
will demonstrate new upright breast biopsy technologies that will
enhance accuracy, workflow and patient experience. She will share
her experiences with the Affirm 2D/3D upright biopsy, lateral arm
approach and Brevera Breast Biopsy system, which integrates tissue
acquisition, real-time imaging and verification, and post-biopsy
sample handling. Dr. Airola will also share cases and explain how
to significantly reduce the time and discomfort to patients in the
biopsy suite while maximizing biopsy suite efficiencies and
clinical decision-making.
- “Emerging Ultrasound Technology in Liver Surveillance”
Monday, Nov. 28: 12:00 p.m. – 1:00 p.m. CST Learn more about the
advancements in ultrasound technology with ShearWave™ Elastography.
There are many opportunities to improve workflow efficiencies in
liver surveillance that drive superior patient experiences and
outcomes. In this lecture, participants will review comparisons
with existing and emerging ultrasound technologies and
techniques.
- “Current AI Applications in Mammography: Focus on Genius AI™
Detection Software” Tuesday, Nov. 29: 12:00 p.m. – 1:00 p.m.
CST Attendees will hear from an expert on the benefits of
artificial intelligence (AI) in mammography screening. With new
high-resolution technologies being implemented, see how AI can
reduce dose, file size and reading times. A focus will be on
deep-learning AI and the benefits of Genius AI Detection software
in clinical decision-making and increasing productivity.
- “Panel Discussion: Options in Localization” Wednesday,
Nov. 30: 12:00 p.m. – 1:00 p.m. CST Join a multidisciplinary
conversation on localization. Hear perspectives from leading
radiologists and breast surgeons about what they like, what they
use and why. What is the role of wires? What other technologies are
available? What are the strengths and weaknesses of different
options?
About Hologic, Inc. Hologic,
Inc. is a global medical technology innovator primarily focused on
improving women’s health and well-being through early detection and
treatment. Its advancements include invention of the world’s first
commercial 3D Mammography™ system to fight breast cancer;
leadership in testing for cervical cancer, sexually transmitted
infections, respiratory illnesses and the virus that causes
COVID-19; and minimally invasive surgical technologies for uterine
fibroids and abnormal uterine bleeding.
The company also champions women through the Hologic Global
Women’s Health Index, which provides a science-backed data roadmap
for improving women’s well-being, and Project Health Equality,
which elevates awareness, research insights and access to quality
care for underserved women. hologic.com
Hologic, 3D Mammography, 3Dimensions, Affirm, Brevera,
Dimensions, Genius AI, I-View, Mach, Selenia, ShearWave,
Supersonic, and The Science of Sure are trademarks and/or
registered trademarks of Hologic, Inc., and/or its subsidiaries in
the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
____________________
1
Publication for reference: Kaur,
Piccolo, Arasaratnam. Implementation of Contrast-Enhanced
Mammography in Clinical Practice, chapter 7, Nori, Kaur (eds.),
Contrast-Enhanced Digital Mammography (CEDM). Springer, 2018.
2
Hobbs MM, Taylor DB, Buzynski S,
and Peake RE. Contrast-enhanced spectral mammography (CESM) and
contrast MRI (CEMRI): Patient preferences and tolerance. Journal of
Medical Imaging and Radiation Oncology. 2015;59:300-305
3
Hologic clinical study CSR-00266
Rev 001 2022
Source: Hologic, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221125005011/en/
Media Contact: Jane Mazur Vice President, Corporate
Communications (+1) 508.263.8764 jane.mazur@hologic.com Investor
Contact: Ryan Simon Vice President, Investor Relations (+1)
858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Jul 2023 to Jul 2024